2nd Quarter - Report

ALKERMES, INC. for ALKERMES, INC.

Firm
Client
Income
—
Expenses
$910,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Maintain six protected classes for depression and schizophrenia under Medicare Part D

LobbyistCovered position, as disclosed
ABIGAIL PINKELE —

Contacted: SENATE; Substance Abuse & Mental Health Services Administration (SAMHSA); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); Justice, Dept of (DOJ); Executive Office of the President (EOP)

Alcohol and Drug Abuse ALC

Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings PL#114-198 Funding and implementation of Comprehensive Addiction and Recovery Act H.R.5786 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019 S.3024 Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2019 H.R.5952 Commerce, Justice, Science and Related Agencies Appropriations Act, 2019 S.3072 115th Congress (2017-2018) Commerce, Justice, Science and Related Agencies Appropriations Act, 2019 S.3156 (2017-2018) Department of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2019 House Discussion Draft, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON —
PETER NORMAN —
ABIGAIL PINKELE —

Contacted: Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Justice, Dept of (DOJ); Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); SENATE; Executive Office of the President (EOP); Substance Abuse & Mental Health Services Administration (SAMHSA); Natl Institutes of Health (NIH)

Bills named: S. 3072 (115th), S. 3024 (115th), H.R. 5952 (115th), H.R. 5786 (115th), S. 3156 (115th)

Health Issues HCR

Awareness of the need for treatment system reform and access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments HR 5327 - Comprehensive Opioid Recovery Centers Act of 2018 S. 2589 - Comprehensive Opioid Recovery Centers Act of 2018 HR 6 - SUPPORT for Patient and Communities Act

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON —
PETER NORMAN —
ABIGAIL PINKELE —

Contacted: Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Executive Office of the President (EOP); Justice, Dept of (DOJ); SENATE; Natl Institutes of Health (NIH)

Bills named: S. 2589 (115th), H.R. 5327 (115th), H.R. 6 (115th)

Pharmacy PHA

Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment

LobbyistCovered position, as disclosed
ROBERT FORMAN —
MEGAN JACKSON —
PETER NORMAN —
ABIGAIL PINKELE —

Contacted: Natl Institutes of Health (NIH); Executive Office of the President (EOP); Substance Abuse & Mental Health Services Administration (SAMHSA); Health & Human Services, Dept of (HHS); Office of Natl Drug Control Policy (NDCP); Justice, Dept of (DOJ); SENATE; HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.